Literature DB >> 18753637

Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.

Norman Nausch1, Ioanna E Galani, Eva Schlecker, Adelheid Cerwenka.   

Abstract

Myeloid-derived suppressor cells (MDSCs) accumulate in cancer patients and tumor-bearing mice and potently suppress T-cell activation. In this study, we investigated whether MDSCs regu-late natural killer (NK)-cell function. We discovered that mononuclear Gr-1(+)CD11b(+)F4/80(+) MDSCs isolated from RMA-S tumor-bearing mice do not suppress, but activate NK cells to produce high amounts of IFN-gamma. Gr-1(+)CD11b(+)F4/80(+) MDSCs isolated from tumor-bearing mice, but not myeloid cells from naive mice, expressed the ligand for the activating receptor NKG2D, RAE-1. NK-cell activation by MDSCs depended partially on the interaction of NKG2D on NK cells with RAE-1 on MDSCs. NK cells eliminated Gr-1(+)CD11b(+)F4/80(+) MDSCs in vitro and upon adoptive transfer in vivo. Finally, depletion of Gr-1(+) cells that comprise MDSCs confirmed their protective role against the NK-sensitive RMA-S lymphoma in vivo. Our study reveals that MDSCs do not suppress all aspects of antitumor immune responses and defines a novel, unexpected activating role of MDSCs on NK cells. Thus, our results have great impact on the design of immune therapies against cancer aiming at the manipulation of MDSCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753637      PMCID: PMC2582006          DOI: 10.1182/blood-2008-03-143776

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D.

Authors:  Leonidas N Carayannopoulos; Olga V Naidenko; Daved H Fremont; Wayne M Yokoyama
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

2.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia.

Authors:  Régis T Costello; Simona Sivori; Emanuela Marcenaro; Marina Lafage-Pochitaloff; Marie-Joelle Mozziconacci; Denis Reviron; Jean-Albert Gastaut; Daniela Pende; Daniel Olive; Alessandro Moretta
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

4.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.

Authors:  Cecilia Melani; Claudia Chiodoni; Guido Forni; Mario P Colombo
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

5.  Role of immature myeloid Gr-1+ cells in the development of antitumor immunity.

Authors:  Qingsheng Li; Ping-Ying Pan; Peidi Gu; Dongping Xu; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

6.  Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Authors:  Sergei Kusmartsev; Yulia Nefedova; Daniel Yoder; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

7.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

8.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.

Authors:  Sergei Kusmartsev; Fengdong Cheng; Bin Yu; Yulia Nefedova; Eduardo Sotomayor; Richard Lush; Dmitry Gabrilovich
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

9.  Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells.

Authors:  Guido Ferlazzo; Ming L Tsang; Lorenzo Moretta; Giovanni Melioli; Ralph M Steinman; Christian Münz
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307

10.  Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

Authors:  Masaki Terabe; So Matsui; Jong-Myun Park; Mizuko Mamura; Nancy Noben-Trauth; Debra D Donaldson; Wanjun Chen; Sharon M Wahl; Steven Ledbetter; Bruce Pratt; John J Letterio; William E Paul; Jay A Berzofsky
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  65 in total

1.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

Review 2.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

3.  Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.

Authors:  Eva Sahakian; John J Powers; Jie Chen; Susan L Deng; Fengdong Cheng; Allison Distler; David M Woods; Jennifer Rock-Klotz; Andressa L Sodre; Je-In Youn; Karrune V Woan; Alejandro Villagra; Dmitry Gabrilovich; Eduardo M Sotomayor; Javier Pinilla-Ibarz
Journal:  Mol Immunol       Date:  2014-08-23       Impact factor: 4.407

4.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

5.  Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Authors:  Tong Zhang; Charles L Sentman
Journal:  Cancer Res       Date:  2011-01-31       Impact factor: 12.701

Review 6.  Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha; Daniel W Beury; Virginia K Clements
Journal:  Semin Cancer Biol       Date:  2012-02-01       Impact factor: 15.707

Review 7.  Myeloid-derived suppressor cells: a double-edged sword?

Authors:  Agnieszka Pastuła; Janusz Marcinkiewicz
Journal:  Int J Exp Pathol       Date:  2011-02-12       Impact factor: 1.925

8.  Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity.

Authors:  Lirong Yang; David A Zaharoff
Journal:  Biomaterials       Date:  2013-02-27       Impact factor: 12.479

9.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16

Review 10.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.